Article
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2012
Gottschling Sandra, Herpel Esther, Eberhardt Wilfried E E, Heigener David F, Fischer Jürgen R, Köhne Claus-Henning, Kortsik Cornelius, Kuhnt Thomas, Muley Thomas, Meister Michael, Bischoff Helge G, Klein Peter, Moldenhauer Ines, Schnabel Philipp A, Thomas Michael, Penzel Roland
Abstract excerpt
BACKGROUND: In selected patients with advanced non-small cell lung cancer (NSCLC) the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) gefitinib (IRESSA) shows response rates of ≥ 70% and a significant prolongation of progression free survival (PFS). However, cogent biomark...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.